Dr Richard Gordon is a network member of the MND Collective at UQ.

Researcher biography

Dr. Richard Gordon leads a multi-disciplinary, industry-partnered research program in Translational Neuroscience which integrates immunology, drug development, pharmacology, metabolomics and microbial metagenomics. His group aims to understand and therapeutically target key pathological mechanisms which drive the onset and progression of neurodegenerative disorders such as Parkinson's disease (PD) and Amyotrophic Lateral Sclerosis (ALS). Their work combines target validation studies in human patients with mechanistic insights from disease models to develop and test novel therapeutic strategies that can be translated towards clinical trials.

Key research themes within this program include:

  • Understanding how chronic immune and inflammasome activation contribute to neurodegeneration in the CNS
  • The role of gut dysbiosis and gastrointestinal dysfunction in Parkinson's disease pathophysiology
  • Therapeutic targeting of the gut-brain axis for neuroprotection
  • Drug discovery, development and repositioning for novel therapeutic targets
  • Discovery and validation of clinical biomarkers for PD and ALS
  • Clinical trials for disease-modifying therapeutic strategies